The ACR’s Affiliate Society Council (ASC) membership has grown from 34 states to 40 since 2015. The growth of the Council is mainly attributed to newly formed state societies, as well as existing state societies focusing on orienting themselves for advocacy on behalf of rheumatologists and their patients. Increased participation by state societies helps support…
Challenges Rheumatologists Will Face in 2017
Rheumatologists and rheumatology health professionals interested in knowing more about the major legislative and regulatory issues that may have an impact on their practice will want to attend the Legislative and Regulatory Update 2016 session at the upcoming ACR/ARHP Annual Meeting. On Tuesday, Nov. 15, from 7:30–8:30 a.m. in Room 140A, Will Harvey, MD, MSc,…
The Fight Against the Medicare Part B Demonstration Project
The ACR and 315 other organizations have publicly said savings would not be achieved by the demonstration project and that it will reduce access to care for patients…
RheumPAC Backs Pro-Rheumatology Congressional Candidate Dr. Matt Heinz from Arizona
RheumPAC is the ACR’s political action committee dedicated to increasing rheumatology’s presence on Capitol Hill. It is the only PAC dedicated to the interests of all rheumatologists and their patients. RheumPAC began in 2007 with the purpose of building contacts, influence and visibility within Washington, D.C. for rheumatology. RheumPAC works to support and elect pro-rheumatology…
Shifting Health Policy Landscape Brings Opportunities, Responsibility to Advocate for Rheumatology
Heraclitus of Ephesus (c. 500 BC) is credited with the saying, “The only constant is change.” Now, centuries later, change is meteoric, and especially in healthcare and health policy, the pace of change is relentless. Rheumatology and other specialties continue to face challenges that threaten the ability to deliver compassionate, competent care to patients. The…
Advocacy Spotlight: Dr. Matt Heinz, Candidate for Congress from Arizona District 2 (Tucson)
RheumPAC is the ACR’s political action committee dedicated to increasing rheumatology’s presence on Capitol Hill. It is the only PAC dedicated to the interests of all rheumatologists and their patients. RheumPAC began in 2007 with the purpose of building contacts, influence and visibility within Washington, D.C. for rheumatology. RheumPAC works to support and elect pro-rheumatology…
The ACR’s Advocates for Arthritis 2016 Legislative Fly-In Heads to Capitol Hill
On Sept. 12–13, ACR advocates will be back on Capitol Hill as part of the Advocates for Arthritis legislative fly-in. This annual event brings together rheumatology professionals and patients to advocate on behalf of the rheumatology community. The core issues on which the advocates will focus this year include advocating for dramatic changes to the…
Rheumatology Research Foundation Investigators’ Meeting Shares Advancements Toward a Cure
The Rheumatology Research Foundation hosted the 9th annual Investigators’ Meeting in Atlanta on June 24–25. As a requirement for Foundation innovative research and pilot grant recipients, Foundation-funded investigators meet annually to provide updates and status reports on the work they are doing to advance treatments and cures for rheumatic diseases. More than 50 attendees enjoyed…
The ACR’s Workforce Study Group to Release 2015 Survey Results
The ACR and its Rheumatology Research Foundation continue to work together to provide support for the rheumatology and patient communities. Both organizations are committed to advancing the field of rheumatology with a dedication to expanding the workforce. With a growing number of patients being diagnosed with a rheumatic disease and living longer with the disease,…
The ACR’s Advocacy at State Legislature Level in 2016 Focuses on Biosimilars, Step Therapy
A majority of state legislatures have concluded their work for 2016. The ACR’s state advocacy efforts continued to focus on policy benefiting rheumatologists and patients alike. The two dominant issues this year were biosimilar substitution and step therapy. Biosimilar Substitution Biosimilar substitution remains the most prevalent issue throughout the states. The ACR continues to monitor…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 29
- Next Page »